Return to Clinical Trials Search Results

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Comb

Primary Outcome Measures : Complete Remission (CR) [ Time Frame: Up to 7 months ] CR is defined as the proportion of participants who achieve CR within 6 cycles of treatment as determined by the investigator while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT). Overall Survival (OS) [ Time Frame: Randomization up to death or end of study (up to 5 years) whichever occurs first ] OS is measured from the date of randomization to the date of death from any cause.

Primary Outcome Measures : Complete Remission (CR) [ Time Frame: Up to 7 months ] CR is defined as the proportion of participants who achieve CR within 6 cycles of treatment as determined by the investigator while on study prior to initiation of any new anti-acute myeloid leukemia (AML) therapy or stem cell transplant (SCT). Overall Survival (OS) [ Time Frame: Randomization up to death or end of study (up to 5 years) whichever occurs first ] OS is measured from the date of randomization to the date of death from any cause.